

- 6 -

CLAIMS

1. Ibopamine maleate salt (1:1).
2. Pharmaceutical composition for ophthalmic use, characterized in that it comprises ibopamine maleate (1:1) together with at least one pharmaceutically acceptable vehicle.
- 5 3. Pharmaceutical composition according to Claim 2, characterized in that it is in the form of an ointment or eyedrops.
4. Pharmaceutical composition according to Claim 2 or 3, characterized in that the amount of ibopamine is between 0.01% and 6% by weight.
- 10 5. Pharmaceutical composition according to Claim 2 or 3, characterized in that the amount of ibopamine is between 0.1% and 5% by weight.
6. Process for preparing the ibopamine maleate salt (1:1), characterized in that it includes the addition of maleic acid, dissolved in a suitable organic solvent, to ibopamine base, also dissolved in a suitable organic solvent, in a 1:1 molar ratio.
- 15 7. Process according to Claim 6, characterized in that the abovementioned addition is performed under an atmosphere of an inert gas.
- 20 8. Process according to Claim 6 or 7, characterized in that the abovementioned addition is performed at room temperature.
9. Process according to any one of the preceding Claims 6 to 8, characterized in that the salt formed is isolated via precipitation and filtration.
- 25 10. Process according to any one of the preceding Claims 6 to 9, characterized in that the abovementioned organic solvent is acetone.
- 30 11. Process according to Claim 10, characterized in that the salt is precipitated from the acetone solution via addition of ethyl ether.